文献速递乳腺MR

乳腺癌患者新辅助化疗后的MRI反应及其预后意义

MRI response to neoadjuvant chemotherapy and prognostic implications in breast cancer patients.
PubMed 文献 · Br J Radiol · 2026-01-01

单中心回顾性队列纳入571例接受新辅助化疗及术前乳腺MRI的乳腺癌患者,按免疫表型分析MRI与病理反应和DFS的关系。放射学与病理反应一致率71.5%,35.2%达rCR、37.5%达pCR;三阴性乳腺癌中非rCR且非pCR者DFS显著更差(HR 7.728,95%CI 2.696-22.149,P<.001)。

要点

  • 三阴性乳腺癌中非rCR且非pCR者复发或死亡风险显著更高(HR 7.728)。
  • 放射学与病理反应总体一致率为71.5%,rCR占35.2%、pCR占37.5%。
  • Luminal型与HER2过表达型中各反应组合间DFS无显著差异。

核心结论

  • 整合新辅助化疗后MRI与病理反应评估可能改善风险分层与预后判断,尤其在三阴性乳腺癌中。

研究设计与样本

  • 单中心、经IRB批准的回顾性队列研究,纳入571例接受新辅助化疗及术前乳腺MRI的连续乳腺癌患者(平均年龄46岁,范围26-90岁);病理反应采用残余肿瘤负荷(RCB)系统评估,pCR定义为无浸润性癌;rCR定义为MRI上无异常强化。

关键影像表现/征象

  • rCR定义为MRI上无异常强化,pCR定义为病理无浸润性癌。
  • 放射学与病理反应一致率为71.5%。
  • Luminal型占42.3%、三阴性占31.5%、HER2过表达型占26.3%。

诊断标准与关键数值

  • pCR采用RCB系统评估,定义为无浸润性癌。
  • rCR定义为MRI上无异常强化。
  • 三阴性乳腺癌中非rCR且非pCR者复发或死亡风险HR 7.728(95%CI 2.696-22.149,P<.001)。
  • Luminal型各反应组合间DFS无显著差异(LogRank P=.505),HER2过表达型亦无显著差异(LogRank P=.257)。
  • 三阴性乳腺癌中无pCR或无rCR者DFS显著差于达任一反应者(LogRank P=.001)。

临床应用与阅片要点

  • 新辅助化疗后术前MRI评估rCR并与病理RCB结果结合,可能有助于三阴性乳腺癌的风险分层。
  • 三阴性乳腺癌中非rCR且非pCR提示预后更差(HR 7.728)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: To correlate response evaluation after neoadjuvant chemotherapy (NAC), assessed by MRI and pathology, with disease-free survival (DFS) in breast cancer patients, according to immunophenotype.

METHODS: Single-centre, IRB-approved retrospective cohort study included consecutive breast cancer patients who underwent NAC and preoperative breast MRI. Pathologic response was evaluated using the residual cancer burden (RCB) system, with pathological complete response (pCR) defined as the absence of invasive carcinoma. Radiological complete response (rCR) was defined as the absence of abnormal enhancement on MRI. The Kaplan-Meier method estimated DFS and Cox regression analysis calculated hazard ratios (HRs).

RESULTS: Five hundred seventy-one patients were included (mean age 46 years, range 26-90). The most common immunophenotype was luminal (42.3%), followed by triple-negative (TNBC, 31.5%) and HER2 overexpressed (26.3%). Radiological and pathological responses were concordant in 71.5%. Overall, 35.2% achieved rCR and 37.5% achieved pCR. Disease-free survival curves did not differ significantly according to radiologic-pathologic response combinations in the luminal or HER2 groups (LogRank P = .505 and P = .257). In the TNBC group, patients without pCR or rCR had significantly worse DFS compared to those achieving either response (LogRank P = .001). Cox regression revealed that TNBC patients with both non-rCR and non-pCR had a markedly higher risk of recurrence or death (HR 7.728; 95% CI 2.696-22.149; P < .001).

CONCLUSIONS: Integrating MRI and pathological response assessments after NAC may enhance risk stratification and prognostication, especially in triple-negative breast cancer.

ADVANCES IN KNOWLEDGE: Patients with both non-rCR and non-pCR have significantly worse DFS, underscoring the prognostic value of combining imaging and pathological findings, particularly in TNBC.

来源:Br J Radiol,查看原文。版权归原作者所有。

引用

  1. Damião SQ, da Cunha EFR, Tavares MC, et al. MRI response to neoadjuvant chemotherapy and prognostic implications in breast cancer patients. Br J Radiol. 2026. PMID: 41615457. doi:10.1093/bjr/tqag023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。